MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

NCT06400589 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2024-05-31

No results posted yet for this study

Summary

The objectives of this study are to compare the efficacy and safety of tanfanercept ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.

Conditions

  • Dry Eye

Interventions

DRUG

tanfanercept

TNF inhibitor

DRUG

Vehicle

Same composition as tanfanercept but without the active ingredient

Sponsors & Collaborators

  • HanAll BioPharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-08-31
Completion
2025-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06400589 on ClinicalTrials.gov